Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...

In a deal valued at much to $3.1 billion, Novartis AG (NYSE:NVS) announced on February 11, 2025, that it would repurchase Anthos Therapeutics and recover the rights to abelacimab, which is a drug that ...

On February 11, NVS entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in ...

“In some patients, physicians and patients find themselves in a difficult situation when a patient is at risk of having a stroke and the patient is at high risk for bleeding,” said Dan Bloomfield, ...

The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation ...

Novartis agreed to a deal worth up to $3.1 billion for Blackstone Life Sciences’ Anthos Therapeutics. Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has ...

Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline ...

Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline candidate ...

On February 11, 2025, the company announced that it is buying back Anthos Therapeutics in a deal worth up to $3.1 billion, reclaiming the rights to abelacimab, a potential breakthrough in stroke ...